Concepedia
5
Publications
81
Citations
H-Index
2017
Active since
Affiliations
Novo Nordisk (United States)(Current)
Cory Gamble is an author at Novo Nordisk (United States).
Publications per year
2017–2023
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective
Dhvani Shah, Nancy Risebrough, Johnna Perdrizet et al. · ClinicoEconomics and Outcomes Research · 2018 · 24 citations · Full text
Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study
William H. Polonsky, Cory Gamble, Neeraj N. Iyer et al. · Diabetes Spectrum · 2021 · 17 citations · Full text
Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry
Suzanne V. Arnold, Kensey Gosch, Mikhail Kosiborod et al. · American Heart Journal · 2023 · 15 citations
Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States
Barnaby Hunt, Ceilidh C. McConnachie, Cory Gamble et al. · Journal of Medical Economics · 2017 · 13 citations
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
Qian Li, Rahul Ganguly, Michael L. Ganz et al. · Diabetes Therapy · 2018 · 12 citations · Full text
Rows per page
1–5 of 5